Đang chuẩn bị liên kết để tải về tài liệu:
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: The GLOW5 study

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Two once-daily long-acting muscarinic antagonists (LAMAs) are currently available for the treatment of chronic obstructive pulmonary disease (COPD) – tiotropium and glycopyrronium. Previous studies have compared glycopyrronium with open-label tiotropium. |

TÀI LIỆU LIÊN QUAN